<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00263198</url>
  </required_header>
  <id_info>
    <org_study_id>05-0970</org_study_id>
    <nct_id>NCT00263198</nct_id>
  </id_info>
  <brief_title>PTK and Letrozole in Post-menopausal Women With Advanced Breast Cancer</brief_title>
  <official_title>Phase II Study of the Combination of PTK787/ZK222584 and Letrozole in Postmenopausal Women With Advanced Hormone Receptor Positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety of PTK787/ZK222584 and Letrozole when given&#xD;
      in combination, and to see what effects they have on breast cancer that has metastasized.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    unacceptable toxicity&#xD;
  </why_stopped>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the effect of the combination of letrozole &amp; PTK787/ZK222584 on disease progression.</measure>
    <time_frame>24 weeks after starting PTK787/ZK222584</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the response rate (CR and PR)</measure>
    <time_frame>Completion of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the safety and tolerability of the combination of drugs</measure>
    <time_frame>30 days after completion of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the pharmacokinetic profiles of the combination of drugs</measure>
    <time_frame>Cycle 3 Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the modulation of tumor blood flow and blood vessel permeability in response to PTK787/ZK222584 when administered in combination with letrozole using Dynamic Contrast-Enhanced Magnetic Resonance Imaging</measure>
    <time_frame>Cycle 1 Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect on circulating tumor cells</measure>
    <time_frame>Completion of treatment</time_frame>
    <description>Determined by the commerical Immunocon cell search assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare outcome of patients receiving letrozole and PTK787/ZK222584 (cases) with control patients from pivotal trials of letrozole in the first and second line setting.</measure>
    <time_frame>30 days after completion of study treatment</time_frame>
    <description>Matching the cases and controls for line of therapy, sites of disease and duration of prior aromatase inhibitor therapy before the study patient initiates PTK787/ZK222584 treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate polymorphisms in relevant drug metabolism genes to determine the molecular basis for interactions between letrozole and PTK787/ZK222584 should they occur.</measure>
    <time_frame>Completion of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlate serum LDH level with clinical response</measure>
    <time_frame>Completion of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>With additional patient consent, collect peripheral blood cells, serum, plasma, and representative tumor tissue specimens for future correlative science studies</measure>
    <time_frame>Baseline visit</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Letrozole + PTK787/ZK222584</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Letrozole 2.5 mg PO daily for 28 days (patients who have already been treated with letrozole for at least 28 days can skip this part)&#xD;
Start cycle 1 with:&#xD;
Letrozole 2.5 mg PO once daily&#xD;
PTK787/ZK222584 250 mg BID PO for 1 week, then 500 mg BID PO for the 2nd week followed by 500 mg qAM and 750 mg QPM PO for the subsequent 2 weeks.&#xD;
Subsequent cycles:&#xD;
PTK787/ZK222584 500 mg qAM and 750 mg qPM PO daily&#xD;
Letrozole 2.5 mg PO once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PTK787/ZK222584</intervention_name>
    <arm_group_label>Letrozole + PTK787/ZK222584</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <arm_group_label>Letrozole + PTK787/ZK222584</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Postmenopausal women with metastatic breast cancer, or loco-regional disease&#xD;
             recurrence not amenable to treatment by surgery or radiotherapy.&#xD;
&#xD;
          -  Postmenopausal status will be defined by any of the following criteria:&#xD;
&#xD;
               -  no spontaneous menses for at least 5 years&#xD;
&#xD;
               -  spontaneous menses within the past 5 years but amenorrheic for at least 12 months&#xD;
                  and estradiol and/or FSH values in the postmenopausal range (while off aromatase&#xD;
                  inhibitor therapy; levels can have been taken while on tamoxifen but in this case&#xD;
                  estradiol should be the parameter assessed)&#xD;
&#xD;
               -  bilateral oophorectomy&#xD;
&#xD;
               -  radiation castration and amenorrheic for at least 3 months&#xD;
&#xD;
               -  the use of an LHRH agonist throughout the duration of the trial (for example&#xD;
                  goserelin 3.6 mg s.c. monthly)&#xD;
&#xD;
          -  Age ≥ 18 years old&#xD;
&#xD;
          -  Patients whose tumors are either estrogen-receptor (ER) and/or progesterone-receptor&#xD;
             (PgR) positive (10% or more infiltrating cancer cells exhibiting nuclear staining).&#xD;
             Patients will be regarded as ER or PgR positive as long as at least one of the tissues&#xD;
             assessed was positive. A positive biochemical test is also acceptable.&#xD;
&#xD;
          -  Patients must have a WHO Performance Status Grade 0-2&#xD;
&#xD;
          -  Newly diagnosed patients who are initiating first line treatment or those patients&#xD;
             with known disease who have shown resistance to anti- estrogen therapy (tamoxifen or&#xD;
             toremifine).&#xD;
&#xD;
          -  Patients currently receiving letrozole or alternative aromatase inhibitors as initial&#xD;
             therapy who are without evidence of progressive disease are eligible.&#xD;
&#xD;
          -  Patients with bone-only metastasis are eligible.&#xD;
&#xD;
          -  Laboratory values ≤ 2 weeks prior to randomization:&#xD;
&#xD;
               -  Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L (≥ 1500/mm3)&#xD;
&#xD;
               -  Platelets (PLT) ≥ 100 x 109/L (≥ 100,000/mm3)&#xD;
&#xD;
               -  Hemoglobin (Hgb) ≥ 9 g/dL&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 ULN&#xD;
&#xD;
               -  Serum bilirubin ≤ 1.5 ULN&#xD;
&#xD;
          -  Aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ≤ 3.0 x&#xD;
             ULN (≤ 5 x ULN if liver metastases present)&#xD;
&#xD;
          -  Negative for proteinuria based on dip stick reading OR, if documentation of +1 result&#xD;
             for protein on dip stick reading, then total urinary protein&#xD;
&#xD;
               -  500 mg and measured creatinine clearance (CrCl) ≥ 50 mL/min from a 24- hour urine&#xD;
                  collection&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks&#xD;
&#xD;
          -  Written informed consent obtained according to local guidelines&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with tumors which are both estrogen and progesterone receptor negative, or&#xD;
             estrogen receptor negative and progesterone receptor unknown or estrogen receptor&#xD;
             unknown and progesterone receptor negative&#xD;
&#xD;
          -  Patients with a history of adrenalectomy or hypophysectomy&#xD;
&#xD;
          -  Patients who developed progressive disease while being treated with an aromatase&#xD;
             inhibitor.&#xD;
&#xD;
          -  Patients with any of the following:&#xD;
&#xD;
               -  Absolute Neutrophil Count &lt; 1.5 x 109/L&#xD;
&#xD;
               -  Hemoglobin &lt; 9 g/dl&#xD;
&#xD;
               -  Platelet count &lt; 100 x 109/L&#xD;
&#xD;
               -  AST and ALT &gt; 3 times the upper limit of normal or &gt; 5 times the upper limit of&#xD;
                  normal if liver metastasis are present&#xD;
&#xD;
               -  Bilirubin &gt; 1.5 upper limit of normal&#xD;
&#xD;
               -  Creatinine &gt; 1.5 x upper limit of normal&#xD;
&#xD;
               -  Calcium &gt; 11.6 mg/dL&#xD;
&#xD;
          -  History or presence of central nervous system (CNS) disease (i.e., primary brain&#xD;
             tumor, malignant seizures, CNS metastases or carcinomatous meningitis)&#xD;
&#xD;
          -  Patients with a history of another primary malignancy ≤ 5 years that has not been&#xD;
             treated for curative intent or that the chance of long term remission is judged to be&#xD;
             less than 50%.&#xD;
&#xD;
          -  Prior chemotherapy &lt;3 weeks prior to registration and/or randomization. Patients must&#xD;
             have recovered from all therapy-related toxicities&#xD;
&#xD;
          -  Prior biologic or immunotherapy ≤ 2 weeks prior to registration and/or randomization.&#xD;
             Patients must have recovered from all therapy-related toxicities&#xD;
&#xD;
          -  Patients with a history of treatment with Fulvestrant or Trastuzumab &lt; 6 months prior&#xD;
             to registration. Patients must have recovered from all therapy- related toxicities in&#xD;
             order to be enrolled.&#xD;
&#xD;
          -  Prior full field radiotherapy ≤ 4 weeks or limited field radiotherapy ≤ 2 weeks prior&#xD;
             to randomization. Patients must have recovered from all therapy-related toxicities.&#xD;
             The site of previous radiotherapy should have evidence of progressive disease if this&#xD;
             is the only site of disease&#xD;
&#xD;
          -  Major surgery (e.g., laparotomy) ≤ 4 weeks prior to randomization. Minor surgery ≤ 2&#xD;
             weeks prior to randomization. Insertion of a vascular access device is not considered&#xD;
             major or minor surgery in this regard. Patients must have recovered from all&#xD;
             surgery-related toxicities&#xD;
&#xD;
          -  Patients who have received investigational drugs ≤ 4 weeks prior to registration&#xD;
             and/or randomization&#xD;
&#xD;
          -  Prior therapy with anti-VEGF agents&#xD;
&#xD;
          -  Peripheral neuropathy with functional impairment ≥ CTC grade 2 neuropathy, regardless&#xD;
             of causality&#xD;
&#xD;
          -  Pleural effusion or ascites that causes respiratory compromise (≥ CTC grade 2 dyspnea)&#xD;
&#xD;
          -  Any of the following concurrent severe and/or uncontrolled medical conditions which&#xD;
             could compromise participation in the study:&#xD;
&#xD;
               -  Uncontrolled high blood pressure (systolic blood pressure &gt; 160 mmHg and/or&#xD;
                  diastolic blood pressure &gt; 95 mmHg), history of labile hypertension, or history&#xD;
                  of poor compliance with an antihypertensive regimen&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Myocardial infarction ≤ 6 months prior to registration and/or randomization&#xD;
&#xD;
               -  Serious uncontrolled cardiac arrhythmia&#xD;
&#xD;
               -  Uncontrolled diabetes (fasting blood sugar &gt; 300 mg/dl)&#xD;
&#xD;
               -  Active or uncontrolled infection&#xD;
&#xD;
               -  Interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the&#xD;
                  lung&#xD;
&#xD;
               -  Patients with prolonged QTc &gt; 470 msec on EKG. All patients with a history of&#xD;
                  congenital or acquired long QTc syndrome.&#xD;
&#xD;
               -  Chronic renal disease&#xD;
&#xD;
               -  Acute or chronic liver disease (e.g., hepatitis, cirrhosis)&#xD;
&#xD;
          -  Impairment of gastrointestinal (GI) function or GI disease that may significantly&#xD;
             alter the absorption of PTK787/ZK 222584 (i.e., ulcerative disease, uncontrolled&#xD;
             nausea, vomiting, diarrhea, malabsorption syndrome, bowel obstruction, or inability to&#xD;
             swallow the tablets)&#xD;
&#xD;
          -  Patients with confirmed diagnosis of human immunodeficiency virus (HIV) infection are&#xD;
             excluded at the investigator's discretion if it is felt that:&#xD;
&#xD;
             1) a potential drug interaction between PTK787/ZK 222584 and any of the patient's&#xD;
             anti-HIV medications could influence the efficacy of the anti-HIV medication, or 2) it&#xD;
             may place the patient at risk due to the pharmacologic activity of PTK787/ZK 222584.&#xD;
             Please refer to appendix for a list of examples of substrates of human liver&#xD;
             microsomal P450 enzymes&#xD;
&#xD;
          -  Patients who are taking therapeutic warfarin sodium (Coumadin) or similar oral&#xD;
             anticoagulants that are metabolized by the cytochrome P450 system. Heparin in any&#xD;
             formulation is allowed. Please refer to appendix for a list of examples of substrates&#xD;
             of human liver microsomal P450 enzymes&#xD;
&#xD;
          -  Patients on P450 enzyme inducing anti-epileptics&#xD;
&#xD;
          -  Patients who are unwilling or unable to comply with protocol requirements.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cynthia Ma, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>December 6, 2005</study_first_submitted>
  <study_first_submitted_qc>December 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2005</study_first_posted>
  <last_update_submitted>May 6, 2013</last_update_submitted>
  <last_update_submitted_qc>May 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Vatalanib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

